BST1

Across TCGA pan-cancer cohorts, BST1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BST1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BST1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BST1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where BST1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.284	0.605	<.001	55	view →
COAD	DFS	Median	II,III,IV	0.878	1.000	.017	30	view →
CCRCC	DFS	Median	III,IV	0.145	0.774	.016	18	view →
LUAD	OS	Quartile	III,IV	0.827	1.000	.031	4	view →
GBM	DFS	Tertile	All	0.560	0.257	.017	2	view →
HNSC	DFS	Median	III,IV	0.939	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BST1–PDAC (DFS)

Open the PDAC breakdown →